Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan · Delayed Price · Currency is TWD 5.51
+0.02 (0.36%)
Aug 19, 2026, 12:55 PM CST
Merdury Biopharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | 4.96 | 1.03 | 2.68 | - | |
Revenue Growth | - | - | 380.44% | -61.46% | - | - |
Cost of Revenue | - | - | 0.78 | 0.44 | 1.51 | - |
Gross Profit | - | - | 4.18 | 0.59 | 1.17 | - |
Selling, General & Admin | 22.62 | 24.37 | 25.57 | 24.91 | 16.66 | 2.48 |
Research & Development | 29.98 | 44.18 | 32.66 | 21.37 | 15.41 | 2.82 |
Operating Expenses | 52.61 | 68.55 | 58.23 | 46.28 | 32.07 | 5.3 |
Operating Income | -52.61 | -68.55 | -54.04 | -45.69 | -30.9 | -5.3 |
Interest Expense | -0.84 | -0.9 | -0.8 | -0.71 | -0.4 | -0.01 |
Interest & Investment Income | 2.57 | 3.2 | 4.11 | 3.07 | 0.33 | 0 |
Currency Exchange Gain (Loss) | -0.2 | -0.2 | 0.21 | - | -0.06 | - |
Other Non Operating Income (Expenses) | 0.03 | -0.21 | - | -0.48 | -0.22 | - |
EBT Excluding Unusual Items | -51.06 | -66.65 | -50.53 | -43.82 | -31.25 | -5.31 |
Gain (Loss) on Sale of Assets | -0.62 | -0.62 | - | - | - | - |
Other Unusual Items | 0.1 | 0.1 | - | - | - | - |
Pretax Income | -51.58 | -67.17 | -50.53 | -43.82 | -31.25 | -5.31 |
Income Tax Expense | 0.04 | 0.06 | 0.04 | - | - | - |
Net Income | -51.62 | -67.23 | -50.57 | -43.82 | -31.25 | -5.31 |
Net Income to Common | -51.62 | -67.23 | -50.57 | -43.82 | -31.25 | -5.31 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 433 | 419 | 416 | 398 | 376 | 277 |
Shares Outstanding (Diluted) | 433 | 419 | 416 | 398 | 376 | 277 |
Shares Change | 2.85% | 0.70% | 4.43% | 5.83% | 36.09% | 165.94% |
EPS (Basic) | -0.12 | -0.16 | -0.12 | -0.11 | -0.08 | -0.02 |
EPS (Diluted) | -0.12 | -0.16 | -0.12 | -0.11 | -0.08 | -0.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -56.69 | -57.72 | -44.73 | -55.07 | -94.35 | -11.77 |
Free Cash Flow Per Share | -0.13 | -0.14 | -0.11 | -0.14 | -0.25 | -0.04 |
Gross Margin | - | - | 84.30% | 57.31% | 43.73% | - |
Operating Margin | - | - | -1088.90% | -4423.04% | -1152.91% | - |
Profit Margin | - | - | -1018.90% | -4241.63% | -1166.05% | - |
Free Cash Flow Margin | - | - | -901.17% | -5331.17% | -3520.60% | - |
EBITDA | -43.89 | -59.67 | -48.15 | -41.62 | -29.15 | -4.73 |
D&A For EBITDA | 8.72 | 8.87 | 5.9 | 4.07 | 1.75 | 0.57 |
EBIT | -52.61 | -68.55 | -54.04 | -45.69 | -30.9 | -5.3 |